Page 6,566«..1020..6,5656,5666,5676,568..6,5806,590..»

Easing Prostate Tx Side Effects

Posted: Published on August 29th, 2012

If your man is undergoing treatment for prostate cancer, you know that the feminizing side effect of breast enlargement can play havoc with his male ego. Although he's surely glad to be a survivor, he would just as surely welcome relief from the dreaded "gynecomastia." Now, Germans researchers hold out hope that tamoxifen, the drug frequently prescribed for breast cancer patients, may bea "potential management option for gynecomastia and breast pain due to non-steroidal antiandrogens." The authors, led by Frank Kunath, published their findings in BMS Medicine. They reviewed four key studies and concluded that the currently available evidence "suggests good efficacy of tamoxifen for the prevention and treatment of breast events induced by non-steroidal antiandrogens. The impact of tamoxifen therapy on long-term adverse events, disease progression and survival remains unclear. Further large, well-designed RCTs, including long-term follow-ups, are warranted. Also, the optimal dose needs to be clarified." A journal news release quotes Dr. Kunath as saying: "Not all men will suffer gynecomastia during anti-androgen therapy. However, if men know that there is a successful option for reducing the breast symptoms associated with treatment for prostate cancer they may be more likely to see their doctor when symptoms of cancer … Continue reading →

Posted in Drug Side Effects | Comments Off on Easing Prostate Tx Side Effects

Drug may ease prostate cancer effects: Study

Posted: Published on August 29th, 2012

Cancer Health Home>>Cancer>>Health news Written by: QMI Agency Aug. 28, 2012 A widely used breast cancer drug may ease the side effects of prostate cancer treatment, according to a new German study. (FOTOLIA) A widely used breast cancer drug may ease the side effects of prostate cancer treatment, according to a new German study. Scientists examined four studies involving men in Europe and North America undergoing drug therapy for prostate cancer, the common side effects of which are gynecomastia (breast enlargement) or breast pain. Those side effects are the most common reasons men stop treatment, said the researchers, who come from medical centres in Nuremberg and Freiburg. The study found that men were less likely to suffer from so-called breast events when their therapy was supplemented with tamoxifen. At 12 months after treatment, men were 22% less likely to have breast enlargement and 25% less likely to have breast pain compared to those taking a different preventative drug, anastrozole. However, while tamoxifen showed "good efficacy" for the prevention and treatment of breast events, more research is needed. "The impact of tamoxifen therapy on long-term adverse events, disease progression and survival remains unclear," the researchers wrote. "Also, the optimal dose needs … Continue reading →

Posted in Drug Side Effects | Comments Off on Drug may ease prostate cancer effects: Study

Number of cancer drugs being rejected by health watchdog rises 50% in two years

Posted: Published on August 29th, 2012

NICE is saying no to more treatments than it did before Cancer Drugs Fund was introduced. campaigners say Fund set up by Government was intended to supplement the number of drugs available Drugs turned down last year include treatments for advanced breast cancer and prostate cancer By Sophie Borland Health Reporter PUBLISHED: 18:40 EST, 28 August 2012 | UPDATED: 18:41 EST, 28 August 2012 The number of cancer drugs being rejected by the health watchdog has risen by 50 per cent in two years, a report has revealed. Campaigners say NICE is saying no to more treatments since the Government introduced its flagship Cancer Drugs Fund, which was meant to supplement the number available. Since 2010, ministers have set aside 200million a year for the fund to pay for cancer drugs which have not been approved by NICE for use on the NHS but which doctors think may help patients. Turned down: Drugs rejected by the health watchdog last year include treatments for advanced breast cancer, bowel cancer and prostate cancer But a leading charity is concerned that since the scheme was set up, the watchdog knows it can afford not to make some drugs available because patients may be … Continue reading →

Posted in Drugs | Comments Off on Number of cancer drugs being rejected by health watchdog rises 50% in two years

North Mississippi police looking for Potts Camp Pharmacy burglary suspect

Posted: Published on August 29th, 2012

North Mississippi police looking for Potts Camp Pharmacy burglary suspect Posted: Tuesday, August 28, 2012 4:22 PM EST Updated: Tuesday, August 28, 2012 4:22 PM EST By WMCTV.com Staff - email News on WMCTV.comNewsMore>> Plans to build new sports center are in the works Plans to build new sports center are in the works Updated: Tuesday, August 28 2012 8:23 PM EDT2012-08-29 00:23:35 GMT Updated: Tuesday, August 28 2012 7:50 PM EDT2012-08-28 23:50:00 GMT Updated: Tuesday, August 28 2012 6:57 PM EDT2012-08-28 22:57:53 GMT Fullilove is now talking about what will happen next. Will this arrest affect her job? Updated: Tuesday, August 28 2012 6:38 PM EDT2012-08-28 22:38:49 GMT Updated: Tuesday, August 28 2012 6:21 PM EDT2012-08-28 22:21:27 GMT (WMC-TV) Marshall County police are trying to track down a pharmacy burglary suspect. Surveillance pictures taken early Monday morning at the Potts Camp Pharmacy on 41 South Center Street in Mississippi show a suspect took several controlled substances. Police are looking for the suspect and vehicle. If you can help, call the North Mississippi crime stoppers at 1-800-729-2169. Continue reading here: North Mississippi police looking for Potts Camp Pharmacy burglary suspect … Continue reading →

Posted in Pharmacy | Comments Off on North Mississippi police looking for Potts Camp Pharmacy burglary suspect

Pharmacy robbed in Franklin County

Posted: Published on August 29th, 2012

Franklin County, MO (KSDK) - Deputies in Franklin County are investigating the armed robbery of a pharmacy in Krakow, Missouri. Police say a man walked into Hall's Pharmacy at 1:45 p.m. Police say he demanded narcotics and left on foot. The suspect is described as a white man in his 20s or 30s standing 5'10" tall with a stocky or muscular build. He was last seen wearing light shorts, a t-shirt, and a gold and black hat. He also had an elastic bandage wrapped around his face. He carried a white bag and said he had a weapon, though he never displayed one. Police believe the suspect may be associated with a health club. Authorities think the suspect entered a blue sporty-type vehicle with spoke or slotted wheels that was parted across Highway A, and drove east on Country Club Road. Police recovered a Mizzou hat and a t-shirt, possibly from "Supplement Super Stores," on Country Club Road. It is believed a second suspect may be involved. He is described as a white male wearing a dark navy Polo shirt and khaki shorts. He has short brown hair, a medium build, and was wearing a tan backpack. Anyone with information … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy robbed in Franklin County

Key Venture Capital Announces Qualifying Transaction With Pharmacy Hearing Centres

Posted: Published on August 29th, 2012

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 28, 2012) - Key Venture Capital Inc. (KVC-P.V) (the "Company"), a capital pool company pursuant to Policy 2.4 of the TSX Venture Exchange (the "TSXV"), is pleased to announce that it has entered into a letter of intent (the "LOI") dated August 27, 2012 for the arm's length acquisition, directly or indirectly, of all of the issued and outstanding shares of Ontario-incorporated PHC Canada Inc. and Delaware-incorporated Pharmacy Hearing Centers, Inc. (collectively "PHC") from the shareholders of VitaSound Audio Inc. ("VitaSound"), a private Ontario corporation. VitaSound is owned as to 38.6% by 2171861 Ontario Inc. (an Ontario company that is directly or indirectly owned equally by Philippe Pango, a resident of the Ivory Coast and Gora Ganguli and Mark Chamberlain, whom are residents of the greater Hamilton area) and as to 17.5% by Trivaris-VitaSound Holdings Inc. (an Ontario company that is controlled by Mark Chamberlain). The LOI contemplates that the Company will, subject to regulatory approval and the approval of the shareholders of the Company and VitaSound, acquire all of the issued and outstanding shares of PHC by way of a share exchange pursuant to which the outstanding securities of PHC will be acquired for … Continue reading →

Posted in Pharmacy | Comments Off on Key Venture Capital Announces Qualifying Transaction With Pharmacy Hearing Centres

Target, Costco Pharmacy Execs Honored by NACDS

Posted: Published on August 29th, 2012

Target and Costco were among those community pharmacy leaders recognized by the National Association of Chain Drug Stores (NACDS) Foundation during the associations recent 2012 NACDS Pharmacy and Technology Conference. The awards in the form of donations made in the name of honorees to help advance NACDS Foundation initiatives -- recognize forward-thinking leaders who have shown a commitment to cultivating the future and the present of healthcare in community pharmacy. The Foundation also recognized pharmacy educators who have made significant contributions to patient care in the community pharmacy setting. The NACDS Foundation, along with our generous donors, recognizes those individuals who, day-to-day, are committed to improving pharmacy education, patient care and healthcare delivery in their communities, said Kathleen Jaeger, NACDS Foundation president. We are honored to recognize these distinguished award recipients, and to support programs that will foster the next generation of patient care. The award recipients were: John Holcomb, Target Corp. VP, healthcare operations: IMS HEALTH awarded the IMS HEALTH Pharmacy Partnership Award to Holcomb, and a contribution of $10,000 was made in Holcombs honor to the NACDS Foundation. The award recognizes a leader who values the importance of data in fact-based communication and will support Foundation efforts to … Continue reading →

Posted in Pharmacy | Comments Off on Target, Costco Pharmacy Execs Honored by NACDS

Vitro Biopharma Advances Commercialization of Its Fertility Drugs: Licensing Partner to Seek Registration in …

Posted: Published on August 29th, 2012

GOLDEN, Colo., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced advances in the commercialization of its infertility treatment drug, Vitropin(TM), a highly purified form of FSH produced through Vitro Biopharma's patented production process. During 2011, Vitro licensed two of its patents and certain rights to other related intellectual property to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies (ART). Dr. Posillico and his team of professionals have recently begun the process of registration of Vitropin(TM) and related products in certain foreign markets. This registration is being pursued together with the establishment of a separate manufacturing contract and various distribution partnerships. Product marketing, distribution and sales will be managed by an international group of professionals that have considerable expertise in the distribution of similar products in the ART feild. The development plan also contemplates registrations for marketing approval of Vitropin(TM) in several additional countries including the US and EU that collectively represent a multi-billion dollar market. Dr. Jim Musick, Vitro Biopharma's President & CEO, said, "We are very pleased to announce commercialization advances related to Vitropin(TM), a product that we previously developed and out-licensed to Dr. Posillico in 2011. Through Vitro Biopharma's license … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Vitro Biopharma Advances Commercialization of Its Fertility Drugs: Licensing Partner to Seek Registration in …

Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis

Posted: Published on August 28th, 2012

Novartis International AG / Novartis drug Jakavi first medication to receive European Commission approval to treat patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Jakavi() (INC424, ruxolitinib) approval based on results from the most extensive myelofibrosis clinical trial program to date * Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival * In Phase III studies, Jakavi reduced spleen size and debilitating manifestations of myelofibrosis by targeting the underlying mechanism of disease Basel, August 28, 2012 - Novartis received approval today from the European Commission for Jakavi() (INC424, ruxolitinib), a JAK 1 and JAK 2 inhibitor for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post- polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. The European Commissions decision was based on positive findings from the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) clinical trial program. "The approval of Jakavi by the European Commission brings an urgently needed new treatment option with the potential to make a real difference in patients lives, … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis

Novelos Therapeutics Developing CLR1502 (GLOW2) Cancer-Targeted Optical Imaging Agent For Intraoperative Tumor Margin …

Posted: Published on August 28th, 2012

MADISON, Wis., Aug. 28, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. GLOW2 is expected to facilitate and enable diagnostic, staging, debulking and curative cancer surgeries intraoperatively in real time. Novelos expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for GLOW2 in the second half of 2013 and begin clinical trials shortly thereafter. "Current imaging modalities are extremely limited in their ability to define tumor margins, thus contributing to the unacceptably high rate of incomplete surgical removal of malignant tissue, which is associated with an increased risk of cancer recurrence," said Sharon Weber, M.D., Professor and Chief of Surgical Oncology, Vice Chair of Academic Affairs for General Surgery, University of Wisconsin Department of Surgery, and Director of Surgical Oncology, Carbone Cancer Center. "The potential for GLOW2 to provide surgeons with more accurate visualization of tumor margins during surgery could result in more complete and selective removal of tumors and significantly improve patient outcomes. I am excited to … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Novelos Therapeutics Developing CLR1502 (GLOW2) Cancer-Targeted Optical Imaging Agent For Intraoperative Tumor Margin …

Page 6,566«..1020..6,5656,5666,5676,568..6,5806,590..»